The AURACIL Story:
Where Science Meets Purpose
Living with eczema means an intimate familiarity with the cycle: the unpredictable flares, the persistent itch, the quiet exhaustion of pursuing every available option with no avail.
Buddhadev Chaudhuri, Ph.D., a drug formulation expert, living with eczema, ran a systematic review of the clinical literature on eczema pathophysiology and skin barrier dysfunction, seeking a non-acute, lasting solution. What emerged was a non-steroidal topical formulation combining 11 natural bioactive ingredients thoughtfully selected to work in harmony with the body's own healing mechanisms. After self applying the formulation, the flares and itch subsided for the first time in years, his skin began to meaningfully recover.
Anjan Chatterji, CEO, Co-founder of AURACIL, who had spent years attempting to manage his own eczema, through conventional therapy with diminishing returns, met Buddhadev on a chance encounter. When he began using the formulation, the results were equally compelling. His treating physician Dr. Kasuganti, noticed his lesion severity was visibly reduced, lichenified skin was progressively normalizing, and the integrity of a long-compromised skin barrier was being restored. Couples with his physician’s confidence, as well as his rapid improvement, compelled Anjan to cofound AURACIL to help patients world-wide.
AURACIL was founded on the principle that lasting skin health is not a luxury, it is an attainable outcome, and that achieving it should never come at the cost of safety or long-term wellbeing. That principle shapes every decision we make and every formulation we develop.